Navigation Links
Forte Research Systems Opens Their OnCore Software Developer Toolkit for Use With Any eIRB System
Date:6/29/2011

MADISON, Wis., June 29, 2011 /PRNewswire/ --

  • OnCore® Software Developer Toolkit (SDK) for eIRB integration now freely available.
  • Toolkit works with any eIRB system, including commercial and homegrown systems.
  • SDK model allows data to flow in either direction between Clinical Trials Management System (CTMS) and eIRB system.
  • Benefits include reduced manual data entry and more timely access to both clinical and regulatory data.

After proving the success of their electronic Institutional Review Board (eIRB) management system integration interface, Forte Research Systems, Inc. is making their Software Developers' Toolkit (SDK) freely available to all interested parties. The integrations were accomplished between Forte Research's market-leading product, the OnCore Clinical Research Management system, and various eIRB systems.

(Logo:  http://photos.prnewswire.com/prnh/20101115/CG02078LOGO)

"As the market leader, we feel this was the right thing to do for our customers, not to mention the clinical research community as a whole," said Srini Kalluri, Founder, President, CEO and Chief Customer Experience Officer at Forte Research Systems. "There's no reason for every one of our customers to have to reinvent the wheel when they want to share data between their eIRB system and OnCore."

The organizations that have implemented the OnCore SDK to exchange data with their eIRB systems cite similar motivations for pursuing this method for systems integration. Goals include reducing the amount of manual data entry, reducing errors by creating a single point of data entry, improving efficiency, supporting more streamlined processes, and increasing the availability of information to the people who need it. Additionally, the SDK model allows data to be inserted into the OnCore database as easily as it may be extracted.

Two NCI-designated Cancer Centers have completed their integration between OnCore and their eIRB systems using the SDK. At the Huntsman Cancer Institute (HCI) in Salt Lake City, Utah, the integration was with their implementation of Click Commerce's eResearch Portal. The other completed implementation is at the University of Virginia Cancer Center, which integrated OnCore with their homegrown eIRB system.

Reducing duplicative data entry and making processes more efficient were the primary goals for the Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill, as well. Their ongoing implementation of the OnCore SDK is focused on cross-populating data between OnCore and a homegrown eIRB system. This information is related to Scientific Review Committee and IRB activities. In addition to review data, information related to protocol staff, protocol sponsors, and general protocol information is an ultimate goal of this data exchange.

"When we get that data to cross-populate between the two systems and we can activate studies more efficiently, that will be a great outcome," said Mary O'Dwyer, Clinical Protocol Office Associate Director at Lineberger.

Currently, there are several vendors in the marketplace who are successfully addressing the needs of IRBs with computerized systems. The OnCore SDK is general purpose and works with any commercial or homegrown system.

"The SDK model for integration has several advantages over a single-purpose interface," said Tony O'Hare, PhD, Co-founder, Vice President of Engineering, and Chief Collaboration Officer at Forte Research Systems. "Perhaps the most important benefit is that the result is available to every OnCore customer regardless of which eIRB system is in place at their institution."

Like all of Forte Research's major development initiatives, the new SDK was developed as part of a collaborative project in which members of the OnCore community worked closely with the company and provided operational expertise throughout the development process.

The "build-it-once" development model that Forte Research implemented for this SDK is the same model the company has taken from the beginning when first developing the OnCore system 11 years ago.

"What we did for CTMS, we are bringing to clinical research systems integration. Our goal is to minimize the cost of services for our customers and eliminate the need for everyone to have to pay over and over again for the same set of tools," Kalluri said.

About Forte Research Systems

Founded in 2000 and headquartered in Madison, Wisconsin, Forte Research Systems, Inc. develops clinical and translational research management software. The company's flagship product, the OnCore® system, is the nation's most widely adopted clinical research platform among academic research organizations and cancer centers. The OnCore platform is the result of over a decade of experience working closely with large research organizations, including institutes funded by the National Institute of Health's Clinical and Translational Science Award (CTSA) program and forty percent of the NCI designated cancer centers. The company's newest offering, the cloud-based Allegro™ product line is built for clinical research operations excellence with no software to install and no systems administration required.

For information about the OnCore clinical research informatics platform, contact Forte Research Systems at (608) 826-6002 or visit the company online at www.ForteResearch.com.


'/>"/>
SOURCE Forte Research Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
2. Endo Pharmaceuticals Launches FORTESTA™ (Testosterone) Gel for Topical Use Class III for Adult Men in the U.S. With Low Testosterone
3. ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor
4. Endo Pharmaceuticals Receives FDA Approval for FORTESTA™ (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone
5. Forte Research Systems Unveils the Allegro™ Research on Demand Cloud-Based Product Line
6. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
7. ForteBio Announces Launch of Protein G Biosensor for Use on Companys Octet® Instruments
8. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
9. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
10. FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
11. Sanofi Enters Into Research Collaboration with Weill Cornell Medical College to Discover New Treatments for Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016  Nearly 30 million people in ... the epidemic of diabetes. 1 However, nearly 40% ... glucose levels (hyperglycemia) and significant glucose variability. 2 These ... including cardiovascular events. If left untreated, hyperglycemia can lead ... disease or blindness. 3 As part ...
(Date:12/6/2016)... , Dec. 6, 2016 With opioids commonly used for ... the prescription drug market that has led to nationwide fatalities. ... to eight times stronger than heroin or morphine, resulting in likelihood ... , ... , vice president, clinical operations, Behavioral Health for HMC HealthWorks, explained ...
(Date:12/6/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... for patients with genomically defined diseases, today announced that ... million in shares of its common stock. In addition, ... option to purchase up to an additional of $18,750,000 ... with the public offering. All shares of common stock ...
Breaking Medicine Technology:
(Date:12/6/2016)... BROOK, Ill. (PRWEB) , ... December 06, 2016 ... ... disruptions in their brain networks that can be seen on a type of ... disease (PD) is a progressive disorder of the central nervous system characterized by ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease are ... serious health problems, such as cardiovascular illness, according to research cited in a ... Periodontics & Dental Implant Center notes that the correlation between periodontal disease and ...
(Date:12/6/2016)... ... ... According to a November 1 article published on Bustle, there ... drinking enough water, which can cause bad breath (known medically as halitosis). Dr. Farzad ... not only helps reduce the possibility of bad breath, but it can provide individuals ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... named Ajdin Camaga as a vice president of sales. , “Ajdin understands that ... “He works hard to understand what each client needs, and is persistent in ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
Breaking Medicine News(10 mins):